Investor profile
Boehringer Ingelheim Venture Fund has backed 18 European tech companies across 24 funding rounds between 2013 and 2024, joining rounds totalling €365M. Most active in Healthtech. Data as of 6 Aug 2026.
Also recorded as: Boehringer Ingelheim
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Abalos Therapeutics | Germany | 1 | €43M |
| NBE-Therapeutics | Switzerland | 3 | €40M |
| Aignostics | Germany | 1 | €32M |
| AMAL | Switzerland | 1 | €29M |
| Rigontec | Germany |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Abalos Therapeutics | Series A | €43M | 2021-10 |
| Aignostics | Series B | €32M | 2024-10 |
| AMAL | Series B | €29M | 2018-11 |
| DiogenX |
| 3 |
| €28M |
| DiogenX | France | 1 | €28M |
| Brainomix | UK | 2 | €27M |
| Eyevensys | France | 2 | €25M |
| STAT-Diagnostica | Spain | 1 | €25M |
| Imcheck Therapeutics | France | 1 | €20M |
| Topas Therapeutics | Germany | 1 | €18M |
| Metabomed | Israel | 1 | €16M |
| Dopavision | Germany | 1 | €12M |
| tacalyx | Germany | 1 | €7.0M |
| Asgard Therapeutics | Sweden | 1 | €6.0M |
| C-mo Medical Solutions | Portugal | 1 | €4.8M |
| Amal Therapeutics | Switzerland | 1 | €2.8M |
| Acousia Therapeutics | Germany | 1 | €2.5M |
| €28M |
| 2023-05 |
| Eyevensys | Series B | €25M | 2020-08 |
| STAT-Diagnostica | Series C | €25M | 2016-04 |
| Imcheck Therapeutics | Other | €20M | 2017-05 |
| Brainomix | Series B | €19M | 2021-12 |
| NBE-Therapeutics | Series C | €19M | 2020-10 |
| NBE-Therapeutics | Series B | €19M | 2016-11 |
